December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Umbralisib monotherapy associated with a 47% response rate in heavily pretreated patients with relapsed/refractory marginal zone lymphoma, follicular lymphoma, or small lymphocytic lymphoma.